New trends in brain computer interfaces (BCI)

New trends in brain computer interfaces (BCI)
Geralt/Pixabay

Source: Geralt/Pixabay

These are exciting times at the intersection of artificial intelligence (AI) and neuroscience. The trend in brain-computer interfaces (BCIs) is toward flexible, less invasive devices that can record brain activity over long periods of time. New types of brain-computer interfaces are rapidly emerging due to the combined power of AI software and hardware innovation in neurotechnology. Recently, two new brain-computer interfaces reflect this trend and the US Food and Drug Administration (FDA) has accelerated clinical trials.

The brain-computer interface market is expected to reach $3.7 billion by 2027 while expanding at a CAGR of 15.5% during 2020-2027, according to Grand View Research. Brain-computer interfaces are a relatively modern technology dating back to the 1970s with the publication of “Toward Direct Brain-Computer Communication” in the Biophysics and Bioengineering Annual Review by Jacques Vidal at the Brain Research Institute at the University of California, Los Angeles (UCLA). AI’s pattern recognition capabilities decode complex brain activity and convert it into digitized commands to operate computers, prosthetics and other external devices.

The FDA’s Innovative Devices Program allows manufacturers to interact with FDA experts during the premarket review phase and provides prioritized review of submissions. Its goal is to enable patients to have more timely access to these device-driven medical devices and combination products that diagnose or treat life-threatening or irreversibly debilitating diseases and conditions by accelerating the process of development, evaluation and review.

Last month, a neurotech startup founded in 2021 called Axoft earned Breakthrough Device Designation from the FDA for its bio-inspired brain computer interface implant that allows chronic communication with the nervous system that can seamlessly integrate with brain tissues. What sets Axoft apart from other brain-computer interface companies is its soft, flexible polymeric material that significantly reduces glial scarring while maintaining a high density of electrodes that can be chronically implanted into the central nervous system. Additionally, the startup says it has 1,000 times more electrode density than existing soft probes and is 10,000 times softer than existing flexible electronics.

Axoft’s neurotechnology was developed from the work of co-founder and scientific advisor Jia Liu, PHD and assistant professor at the Harvard School of Engineering and Applied Sciences. Earlier this year, Lui and a team from Harvard University published a study in advanced materials demonstrating continuous, noninvasive pairing of neurons with electrodes to perform long-term uninterrupted recording and capture of single-cell action potentials from a human-induced pluripotent stem cell brain organoid using stretchable electrode arrays.

“The stretchable electrode arrays embedded throughout the tissue show no disruption in brain organoid development, adapt to volume and morphological changes during organoid brain organogenesis, and provide long-term stable electrical contacts with neurons within the organoids.” brain organoids during development,” Liu and his team reported. study co-authors at Harvard University.

In August 2022, Synchron’s innovative Stentrode brain computer interface was implanted in an American as part of the Mount Sinai Health System in New York City as part of Synchron’s COMMAND US clinical trial. What makes the Stentrode revolutionary is that it is administered via a catheter and inserted into the body through the jugular vein and then guided into the superior sagittal sinus, a large vessel that fits between the two hemispheres in the brain. Furthermore, the signal quality of the Stentrode does not attenuate over time, showing great potential as a long-term chronic implant.

“This is an incredible innovation in brain-computer interface technology,” said COMMAND principal investigator David Putrino, Ph.D., PT, director of rehabilitation innovation at Mount Sinai Health System and associate professor of medicine at rehabilitation at the Icahn School of Medicine. Medicine at Mount Sinai. “I think we’re going to see a lot of people doing the same thing because it’s a novel way to access and record brain activity.”

Copyright © 2022 Cami Rosso All rights reserved.

Leave a Comment